Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03251365 | Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 42 | Hospital General de Ciudad RealOTHER | 1 | Aug 16, 2017 | clinicaltrials |
| NCT01195415 | Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2017 | clinicaltrials |
| NCT01040000 | QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer | completed | Phase 1 / Phase 2 | 94 | Precision Biologics, IncINDUSTRY | 1 | Aug 4, 2017 | clinicaltrials |
| NCT01303029 | Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer(GECA) | completed | Phase 2 | 120 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT02035072 | Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer. | completed | Phase 2 | 40 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT01729481 | Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer(ML22774) | unknown | Phase 2 | 150 | Ludwig-Maximilians - University of MunichOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 0 | Jul 19, 2017 | clinicaltrials |
| NCT00609336 | Perioperative Therapy for Resectable Pancreatic Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT01016483 | Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer | completed | Phase 1 / Phase 2 | 141 | EMD SeronoINDUSTRY | 2 | Jul 13, 2017 | clinicaltrials |
| NCT02117258 | Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma(ZIPANG) | completed | Phase 2 | 167 | Zeria PharmaceuticalINDUSTRY | 3 | Jul 2, 2017 | clinicaltrials |
| NCT03204019 | A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor | unknown | Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT01273805 | Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01515046 | Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer(PACMAN-II) | terminated | Phase 2 | 1 | Joseph J. CullenOTHER | 1 | Jun 8, 2017 | clinicaltrials |
| NCT00424827 | A Trial of Chemo & Radiation Therapy for Pancreatic Cancer | completed | Phase 2 | 11 | University of Massachusetts, WorcesterOTHER | 0 | Jun 1, 2017 | clinicaltrials |
| NCT00376987 | Zinc Supplements in Lowering Cadmium Levels in Smokers | completed | Phase 2 | 61 | Wake Forest University Health SciencesOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00534001 | Bupropion in Helping Adults Stop Smoking | completed | Phase 2 | 95 | Roswell Park Cancer InstituteOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00841035 | 7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients | terminated | Phase 2 | 6 | University of Alabama at BirminghamOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT01608711 | A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 | completed | Phase 2 | 2 | Agensys, Inc.INDUSTRY | 2 | May 16, 2017 | clinicaltrials |
| NCT01844817 | Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer(Rainier) | completed | Phase 2 | 132 | SCRI Development Innovations, LLCOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT02243007 | Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer | terminated | Phase 2 | 7 | Massachusetts General HospitalOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT00366457 | Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer | completed | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | terminated | Phase 2 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 4 | May 15, 2017 | clinicaltrials |
| NCT00691054 | Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy | completed | Phase 2 | 20 | University of MiamiOTHER | 2 | May 11, 2017 | clinicaltrials |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01272791 | Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer | completed | Phase 2 | 70 | Peregrine PharmaceuticalsINDUSTRY | 2 | Apr 19, 2017 | clinicaltrials |
| NCT00585078 | Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma | completed | Phase 2 | 40 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 10, 2017 | clinicaltrials |
| NCT00550836 | Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 104 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT00601627 | Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery | completed | Phase 2 | 52 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT02461836 | Study of Stereotactic Body Radiation Therapy for Patients After Radical Resection of Pancreatic Cancer With Advanced Stages (T3 or N1) | unknown | Phase 2 | 513 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT00609765 | Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors | terminated | Phase 2 | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT00907166 | A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients | terminated | Phase 1 / Phase 2 | 6 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT01175733 | Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer(Vectibix) | completed | Phase 1 / Phase 2 | 18 | Amsterdam UMC, location VUmcOTHER | 1 | Mar 20, 2017 | clinicaltrials |
| NCT00536874 | Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery | completed | Phase 2 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT01130142 | A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 122 | Infinity Pharmaceuticals, Inc.INDUSTRY | 2 | Mar 6, 2017 | clinicaltrials |
| NCT01895790 | Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients With Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Johns Hopkins UniversityOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00947167 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | terminated | Phase 2 | 4 | Pamela L. KunzOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01108458 | A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma | terminated | Phase 2 | 1 | George Albert FisherOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01581307 | Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets | completed | Phase 2 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00470535 | Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer | terminated | Phase 2 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00944463 | Trial of Simvastatin and Gemcitabine in Pancreatic Cancer Patients | completed | Phase 2 | 106 | Samsung Medical CenterOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT00350142 | Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer | completed | Phase 2 | 20 | Albert KoongOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT02242409 | Study of Gemcitabine and Abraxane for Pancreas Cancer | terminated | Phase 2 | 4 | Georgetown UniversityOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT00093782 | Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02109341 | Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer(NabucCO) | completed | Phase 1 / Phase 2 | 148 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | terminated | Phase 2 | 2 | Emory UniversityOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01964534 | Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer(AFUGEM) | unknown | Phase 2 | 114 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT03016637 | Pancreatic Core Biopsy Needle Study in Patients Suspected of Pancreatic Malignancy(PANCOBE) | completed | Phase 1 / Phase 2 | 40 | Odense University HospitalOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT03013712 | A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer(CARTEPC) | unknown | Phase 1 / Phase 2 | 60 | First Affiliated Hospital of Chengdu Medical CollegeOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT02124317 | Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer(NAPSPAC) | unknown | Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | Dec 22, 2016 | clinicaltrials |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET(COOPERATE-2) | terminated | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 19 | Dec 20, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Aug 16, 2017source: clinicaltrials